Evauating the effects of oral N-acetylcysteinas in comparing with pregabalin for pain managementinpatients with painful diabetic neuropathy.

Phase 2

Recruiting

• Conditions: Diabetic Polyneuropathy.; Type 2 diabetes mellitus with diabetic polyneuropathy; E11.42

• Registration Number: IRCT20180814040795N1
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 14 January 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

Age 30 to 70 years old
History of DM2 at least one year ago
Hb A1C less than or equal to 9
Diabetic Neuropathy with NDS score greater than or equal to 6; VAS Score fore pain at least 4 and NSS score greater than or equal to 5.
Glomerular filteration rate more than 30cc/min

Exclusion Criteria

Type 1 diabetes
Pregnancy or breast feeding
Diabetic foot ulcer
Neuropathy for reason other than diabetes
History of cerebrovascular disease and discopathy
Use other medications to relieve symptoms of neuropathy
Use of alcoholic drink or opioids

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Visual analogue scale. Timepoint: Before intervention, the end of the first month and the end of the second month. Method of measurement: Indicator.;Sleep interference score. Timepoint: Before intervention, the end of the first month and the end of the second month. Method of measurement: Questionnaire.;Patient global impression of change. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Questionnaire.;Clinical global impression of change. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Questionnaire.